Cantor Fitzgerald lowered the firm’s price target on Alkermes (ALKS) to $43 from $48 and keeps an Overweight rating on the shares. Alkermes reported Q3 revenues below consensus estimates but in line with the firm’s expectations, the analyst tells investors in a research note. The firm continues to see Alkermes as an underappreciated Neuro-Innovator and an attractive buying opportunity for long-term investors, and is intrigued by the company’s broadening perspective on the potential use of OX2Rag pharmacology beyond NT and IH, with prospects for treating high burden fatigue and sleepiness symptoms of other neuropsychiatric indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALKS:
- Alkermes price target lowered to $30 from $32 at Goldman Sachs
- Alkermes price target lowered to $37 from $38 at Piper Sandler
- Alkermes backs FY24 financial expectations
- Alkermes reports Q3 adjusted EPS 72c, consensus 74c
- ALKS Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
